GSK's Immunology Strategy Edges Closer To Delivering

GlaxoSmithKline is working to establish an immuno-inflammation portfolio and extend learnings to other therapy areas. Sirukumab could be GSK's first new product in I&I beyond Benlysta. Chief Immunology Officer Paul-Peter Tak outlined his strategy in an interview with Scrip.

Best known for developing respiratory drugs, HIV medicines and vaccines, GlaxoSmithKline PLC has ambitions to become an immuno-inflammation powerhouse. A five-year initiative to establish a pipeline of drugs in the area could deliver its first product to the commercial market next year.

GSK announced Sept. 23 that a BLA for the human anti-interleukin-6 (IL-6) antibody sirukumab was filed with FDA for the...